CA2630415A1 - Marquage de parties fc pour l'immunocoloration et l'immunociblage - Google Patents

Marquage de parties fc pour l'immunocoloration et l'immunociblage Download PDF

Info

Publication number
CA2630415A1
CA2630415A1 CA002630415A CA2630415A CA2630415A1 CA 2630415 A1 CA2630415 A1 CA 2630415A1 CA 002630415 A CA002630415 A CA 002630415A CA 2630415 A CA2630415 A CA 2630415A CA 2630415 A1 CA2630415 A1 CA 2630415A1
Authority
CA
Canada
Prior art keywords
molecule
protein
targeting
amino acid
reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002630415A
Other languages
English (en)
Inventor
Carlos F. Barbas, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
The Scripps Research Institute
Carlos F. Barbas, Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute, Carlos F. Barbas, Iii filed Critical The Scripps Research Institute
Publication of CA2630415A1 publication Critical patent/CA2630415A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002630415A 2005-10-20 2006-10-20 Marquage de parties fc pour l'immunocoloration et l'immunociblage Abandoned CA2630415A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72882105P 2005-10-20 2005-10-20
US60/728,821 2005-10-20
PCT/US2006/060127 WO2007048127A2 (fr) 2005-10-20 2006-10-20 MARQUAGE DE PARTIES Fc POUR L'IMMUNOCOLORATION ET L'IMMUNOCIBLAGE

Publications (1)

Publication Number Publication Date
CA2630415A1 true CA2630415A1 (fr) 2007-04-26

Family

ID=37963426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002630415A Abandoned CA2630415A1 (fr) 2005-10-20 2006-10-20 Marquage de parties fc pour l'immunocoloration et l'immunociblage

Country Status (5)

Country Link
US (1) US20070122408A1 (fr)
EP (1) EP1945262A2 (fr)
JP (1) JP2009512443A (fr)
CA (1) CA2630415A1 (fr)
WO (1) WO2007048127A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116742A2 (fr) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Conjugues de nanoparticules
CA2609702C (fr) * 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Conjugats d'anticorps par lieurs heterobifonctionnels
JP5199880B2 (ja) * 2005-11-23 2013-05-15 ベンタナ・メデイカル・システムズ・インコーポレーテツド 分子コンジュゲート
WO2008134761A2 (fr) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification des groupes de ciblage biologiques pour le traitement du cancer
EP2214700A4 (fr) * 2007-11-02 2012-08-22 Janssen Biotech Inc Produits d'assemblage semi-synthétiques obtenus par fusion de peptide glp-1/fc, procédés et utilisations
WO2010078376A2 (fr) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Anticorps conjugués à un polymère spécifiques de fc et leur utilisation en diagnostic
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
US20110135630A1 (en) * 2009-07-13 2011-06-09 Tolbert Thomas J Chemical modification of antibody fragments
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
EP3610889A1 (fr) * 2011-05-08 2020-02-19 LegoChem Biosciences, Inc. Conjugués d'agent actif de protéine et leur procédé de préparation
WO2013092998A1 (fr) 2011-12-23 2013-06-27 Innate Pharma Conjugaison enzymatique d'anticorps
EP2810069A4 (fr) * 2012-02-03 2015-08-12 Univ Alberta Procédé de quantification de bibliothèques de dérivés peptidiques utilisant l'exposition sur phage
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (fr) 2012-11-09 2014-05-15 Innate Pharma Etiquettes de reconnaissance pour la conjugaison à médiation par la tgase
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
DK2968495T3 (da) * 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
MX2016011934A (es) 2014-03-14 2017-04-13 J Capon Daniel Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
US10988531B2 (en) 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
WO2021216954A1 (fr) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions et méthodes de traitement ou de prévention d'une infection virale

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5218137A (en) * 1989-08-29 1993-06-08 Duke University Light activated acyl-enzymes
US5114851A (en) * 1989-08-29 1992-05-19 Duke University Light activated acyl-enzymes
JPH05509294A (ja) * 1990-04-06 1993-12-22 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション 血栓症治療のための方法および組成物
JPH06502643A (ja) * 1990-11-01 1994-03-24 スミスクライン・ビーチャム・コーポレイション フィブリノーゲン拮抗剤としてのγ−ターンペプチド模倣化合物
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
EP0677043A1 (fr) * 1992-12-29 1995-10-18 Smithkline Beecham Corporation Composes inhibant l'aggregation des plaquettes
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US6403578B1 (en) * 1993-12-21 2002-06-11 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
WO1996006087A1 (fr) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Composes bicycliques
JPH10510537A (ja) * 1994-12-13 1998-10-13 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
EP0796098A4 (fr) * 1994-12-22 1998-04-29 Smithkline Beecham Corp Antagonistes des recepteurs du fibrinogene
US5795893A (en) * 1994-12-22 1998-08-18 Smithkline Beecham Corporation Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5767071A (en) * 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US6008213A (en) * 1995-06-29 1999-12-28 Smithkline Beecham Corporation Integrin receptor antagonists
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
ES2161373T3 (es) * 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
EP0906103A1 (fr) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine
AU2323897A (en) * 1996-03-29 1997-10-22 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
CA2250690A1 (fr) * 1996-03-29 1997-10-09 G.D. Searle & Co. Derives de l'acide cinnamique et leur utilisation comme antagonistes de l'integrine
ATE212978T1 (de) * 1996-03-29 2002-02-15 Searle & Co Para-substituierte phenylpropansäure derivate als integrin-antagonisten
EP0889876B1 (fr) * 1996-03-29 2001-07-25 G.D. SEARLE & CO. Derives meta-substitues du sulphonamide de phenylene
GB9608510D0 (en) * 1996-04-25 1996-07-03 Medical Res Council Calcium dependent binding ligands
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6211184B1 (en) * 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
NZ334438A (en) * 1996-09-03 2000-10-27 Smithkline Beecham Corp (S)-7-[(4,4'-bipiperidrin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid hydrochloride as a platelet aggregation inhibitor
KR19990076764A (ko) * 1996-10-25 1999-10-15 히라타 다다시 래디시콜 유도체
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
US6218387B1 (en) * 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6088213A (en) * 1997-07-11 2000-07-11 Applied Materials, Inc. Bipolar electrostatic chuck and method of making same
US6239138B1 (en) * 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
US6066648A (en) * 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6028087A (en) * 1998-01-21 2000-02-22 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
IL138093A0 (en) * 1998-03-31 2001-10-31 Du Pont Pharm Co Pharmaceuticals for the imaging of angiogenic disorders
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6319937B1 (en) * 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
EP1150965A4 (fr) * 1999-02-03 2002-05-15 Merck & Co Inc Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
EP1028114A1 (fr) * 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Nouveaux dérivés de guanidine et leur utilisation comme inhibiteurs de l'adhésion des cellules
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
EP1446418B1 (fr) * 2001-10-22 2012-05-23 The Scripps Research Institute Composes de ciblage de l'integrine
WO2003059251A2 (fr) * 2001-10-22 2003-07-24 The Scripps Research Institute Composes de ciblage d'anticorps
EP2341134B1 (fr) * 2003-01-31 2014-08-27 Promega Corporation Fixation covalente de groupes fonctionnels à des protéines
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
WO2006069246A2 (fr) * 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2069396B1 (fr) * 2006-09-08 2015-10-21 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations

Also Published As

Publication number Publication date
EP1945262A2 (fr) 2008-07-23
WO2007048127A9 (fr) 2007-06-07
WO2007048127A3 (fr) 2008-10-23
WO2007048127A2 (fr) 2007-04-26
US20070122408A1 (en) 2007-05-31
JP2009512443A (ja) 2009-03-26

Similar Documents

Publication Publication Date Title
CA2630415A1 (fr) Marquage de parties fc pour l'immunocoloration et l'immunociblage
EP1443963B1 (fr) Composes de ciblage d'anticorps
Liu et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors
JP4541693B2 (ja) Ｃｄ１０活性化プロドラッグ化合物
US8809504B2 (en) Inhibitor which is deactivatable by a reagent produced by a target cell
KR101216008B1 (ko) 바이포달 펩타이드 바인더
AU2002337954B2 (en) Integrin targeting compounds
US8846861B2 (en) Peptide clearing agents
RU2689689C2 (ru) Конъюгаты антитело-уреаза для терапевтических целей
JP5677454B2 (ja) 細胞内ターゲット結合用二座ペプチドバインダー
AU2002337954A1 (en) Integrin targeting compounds
Roh et al. Cell-type-specific intracellular protein delivery with inactivated botulinum neurotoxin
TWI396550B (zh) 在生理條件下具升高酵素活性的人類β－葡萄糖醛酸酶突變物及識別該酶之方法
He et al. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
Cordova et al. Aminopeptidase P mediated targeting for breast tissue specific conjugate delivery
CN117959457A (zh) 一种用作靶蛋白降解剂的双功能化合物及其在靶蛋白溶酶体降解中的应用
US20130123192A1 (en) Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration

Legal Events

Date Code Title Description
FZDE Discontinued